145 related articles for article (PubMed ID: 1819866)
21. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease.
Winterkamp S; Weidenhiller M; Otte P; Stolper J; Schwab D; Hahn EG; Raithel M
Am J Gastroenterol; 2002 Dec; 97(12):3071-7. PubMed ID: 12492192
[TBL] [Abstract][Full Text] [Related]
22. [Colicinogens in nonspecific intestinal inflammation. I. Colicinotypes in patients with ulcerous colitis, Crohn's disease and in healthy individuals].
Bures J; Horák V; Buresová E; Fixa B; Komárková O
Cesk Gastroenterol Vyz; 1983 Mar; 37(2):81-6. PubMed ID: 6342822
[No Abstract] [Full Text] [Related]
23. Risk factors of colorectal cancer in inflammatory bowel disease.
Bansal P; Sonnenberg A
Am J Gastroenterol; 1996 Jan; 91(1):44-8. PubMed ID: 8561142
[TBL] [Abstract][Full Text] [Related]
24. Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer.
Tsai WS; Changchien CR; Yeh CY; Chen JS; Tang R; Chiang JM; Hsieh PS; Fan CW; Wang JY
Dis Colon Rectum; 2006 Jun; 49(6):883-94. PubMed ID: 16741643
[TBL] [Abstract][Full Text] [Related]
25. Quantitative analysis of bacterial DNA from Mycobacteria spp., Bacteroides vulgatus, and Escherichia coli in tissue samples from patients with inflammatory bowel diseases.
Fujita H; Eishi Y; Ishige I; Saitoh K; Takizawa T; Arima T; Koike M
J Gastroenterol; 2002; 37(7):509-16. PubMed ID: 12162408
[TBL] [Abstract][Full Text] [Related]
26. [Colicinogeny in colorectal cancer].
Bures J; Horák V; Fixa B; Komárková O; Zaydlar K; Erben J; Lonský V; Preis J; Masurka V
Vnitr Lek; 1985 Jul; 31(7):693-9. PubMed ID: 3901502
[No Abstract] [Full Text] [Related]
27. Incidence of lysogenic, colicinogenic and siderophore-producing strains among human non-pathogenic Escherichia coli.
Smarda J; Smajs D; Horynová S
Folia Microbiol (Praha); 2006; 51(5):387-91. PubMed ID: 17176757
[TBL] [Abstract][Full Text] [Related]
28. Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma.
Pfannschmidt J; Bade S; Hoheisel J; Muley T; Dienemann H; Herpel E
Thorac Cardiovasc Surg; 2009 Oct; 57(7):403-8. PubMed ID: 19795327
[TBL] [Abstract][Full Text] [Related]
29. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer.
Engelhardt M; Drullinsky P; Guillem J; Moore MA
Clin Cancer Res; 1997 Nov; 3(11):1931-41. PubMed ID: 9815582
[TBL] [Abstract][Full Text] [Related]
30. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
31. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
32. Levels of soluble intercellular adhesion molecule-1 and total sialic acid in serum of patients with colorectal cancer.
Basoglu M; Yildirgan MI; Taysi S; Yilmaz I; Kiziltunc A; Balik AA; Celebi F; Atamanalp SS
J Surg Oncol; 2003 Jul; 83(3):180-4. PubMed ID: 12827689
[TBL] [Abstract][Full Text] [Related]
33. Fecal neutral steroids in normal conditions and in patients with polyps or cancer of the large bowel.
Ponz de Leon M; Roncucci L; di Donato P; Sacchetti C; Pezcoller C; Annoni C; Bertani C; Rebecchi P; Balli F; Galli D
Cancer Res; 1987 Jan; 47(1):305-10. PubMed ID: 3791216
[TBL] [Abstract][Full Text] [Related]
34. Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6.
Weg-Remers S; Hildebrandt U; Feifel G; Moser C; Zeitz M; Stallmach A
Am J Gastroenterol; 1998 May; 93(5):790-4. PubMed ID: 9625129
[TBL] [Abstract][Full Text] [Related]
35. Tumor markers in staging and prognosis of colorectal carcinoma.
Levy M; Visokai V; Lipska L; Topolcan O
Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
[TBL] [Abstract][Full Text] [Related]
36. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
[TBL] [Abstract][Full Text] [Related]
37. [Colicinogens in nonspecific intestinal inflammations. II. Test of leukocyte migration inhibition with colicins].
Bures J; Horák V; Buresová E; Fixa B; Komárková O
Cesk Gastroenterol Vyz; 1983 Apr; 37(3):186-90. PubMed ID: 6347404
[No Abstract] [Full Text] [Related]
38. Changes in the Abundance of Faecalibacterium prausnitzii Phylogroups I and II in the Intestinal Mucosa of Inflammatory Bowel Disease and Patients with Colorectal Cancer.
Lopez-Siles M; Martinez-Medina M; Surís-Valls R; Aldeguer X; Sabat-Mir M; Duncan SH; Flint HJ; Garcia-Gil LJ
Inflamm Bowel Dis; 2016 Jan; 22(1):28-41. PubMed ID: 26595550
[TBL] [Abstract][Full Text] [Related]
39. The influence of bacteriocins on resistance to infection by gram-negative bacteria. II. Colicin action, transfer of colicinogeny, and transfer of antibiotic resistance in urinary infections.
Braude AI; Siemienski JS
J Clin Invest; 1968 Aug; 47(8):1763-73. PubMed ID: 4875004
[TBL] [Abstract][Full Text] [Related]
40. Colicins--exocellular lethal proteins of Escherichia coli.
Smarda J; Smajs D
Folia Microbiol (Praha); 1998; 43(6):563-82. PubMed ID: 10069005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
